Raymond James Financial Services Advisors Inc. raised its stake in Humana Inc. (NYSE:HUM – Get Rating) by 5.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,827 shares of the insurance provider’s stock after acquiring an additional 531 shares during the quarter. Raymond James Financial Services Advisors Inc.’s holdings in Humana were worth $4,769,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. Castleview Partners LLC lifted its holdings in shares of Humana by 46,704.0% in the second quarter. Castleview Partners LLC now owns 11,701 shares of the insurance provider’s stock worth $25,000 after acquiring an additional 11,676 shares during the last quarter. Jones Financial Companies Lllp bought a new position in shares of Humana in the second quarter worth about $29,000. WFA of San Diego LLC bought a new position in shares of Humana in the second quarter worth about $30,000. Newbridge Financial Services Group Inc. lifted its holdings in shares of Humana by 42.3% in the second quarter. Newbridge Financial Services Group Inc. now owns 74 shares of the insurance provider’s stock worth $35,000 after acquiring an additional 22 shares during the last quarter. Finally, Ritter Daniher Financial Advisory LLC DE bought a new position in Humana in the 2nd quarter valued at approximately $42,000. Institutional investors own 93.38% of the company’s stock.
Humana Stock Performance
Shares of HUM stock opened at $493.00 on Thursday. The company has a market cap of $62.41 billion, a price-to-earnings ratio of 22.36, a price-to-earnings-growth ratio of 1.25 and a beta of 0.76. Humana Inc. has a 52 week low of $363.73 and a 52 week high of $571.30. The company has a quick ratio of 1.35, a current ratio of 1.35 and a debt-to-equity ratio of 0.48. The firm has a 50 day moving average of $524.53 and a 200-day moving average of $503.94.
Humana Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, January 27th. Investors of record on Friday, December 30th will be given a $0.7875 dividend. This represents a $3.15 annualized dividend and a yield of 0.64%. The ex-dividend date of this dividend is Thursday, December 29th. Humana’s payout ratio is currently 14.29%.
Insider Activity at Humana
In related news, CAO William Kevin Fleming sold 11,157 shares of Humana stock in a transaction on Thursday, November 3rd. The shares were sold at an average price of $565.61, for a total value of $6,310,510.77. Following the completion of the sale, the chief accounting officer now owns 2,542 shares of the company’s stock, valued at approximately $1,437,780.62. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Humana news, CAO William Kevin Fleming sold 11,157 shares of the firm’s stock in a transaction on Thursday, November 3rd. The stock was sold at an average price of $565.61, for a total transaction of $6,310,510.77. Following the transaction, the chief accounting officer now directly owns 2,542 shares in the company, valued at approximately $1,437,780.62. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Bruce D. Broussard sold 9,000 shares of the firm’s stock in a transaction on Thursday, November 3rd. The shares were sold at an average price of $566.17, for a total value of $5,095,530.00. Following the transaction, the chief executive officer now owns 80,564 shares in the company, valued at $45,612,919.88. The disclosure for this sale can be found here. In the last 90 days, insiders sold 51,570 shares of company stock valued at $27,938,777. 0.39% of the stock is owned by company insiders.
Wall Street Analysts Forecast Growth
HUM has been the subject of a number of research reports. Morgan Stanley raised their price objective on shares of Humana from $549.00 to $620.00 and gave the company an “overweight” rating in a report on Monday, October 31st. The Goldman Sachs Group upgraded shares of Humana from a “neutral” rating to a “buy” rating and raised their price objective for the company from $575.00 to $652.00 in a report on Tuesday, December 13th. Mizuho raised their price objective on shares of Humana from $529.00 to $615.00 and gave the company a “buy” rating in a report on Thursday, November 10th. Deutsche Bank Aktiengesellschaft upgraded shares of Humana from a “hold” rating to a “buy” rating and raised their price objective for the company from $514.00 to $576.00 in a report on Wednesday, October 26th. Finally, StockNews.com upgraded shares of Humana from a “buy” rating to a “strong-buy” rating in a report on Friday, November 4th. Two investment analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $602.50.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
- Get a free copy of the StockNews.com research report on Humana (HUM)
- Bloom Energy Powers Up After an Upgrade, is it Worth the Risk?
- Why Hershey Is a Sweet Recession Stock
- Will Amazon Stock Be Delivering for Investors in 2023?
- The Analysts Shift Trucking Sentiment Back into Forward
- The Institutions Book A Flight With Boeing
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.